Theravance Biopharma

March 13, 2019March 13, 2019

First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis

News

Theravance Biopharma announced that the first patient has been dosed in a Phase 2b/3 study to test the efficacy and safety of its candidate oral drug TD-1473 for the treatment ... Read more

February 9, 2018

Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases

News

Theravance Biopharma Ireland Limited, a Theravance Biopharma subsidiary, and Janssen Biotech have joined forces to develop and commercialize the investigational therapy TD-1473 as a treatment for inflammatory bowel diseases (IBDs) such ... Read more

August 11, 2017August 16, 2017

Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial

News, Ulcerative colitis

Early data from a Phase 1b clinical trial show that the investigational therapy TD-1473 for patients with ulcerative colitis (UC) has demonstrated targeted action and effectiveness, according to the therapy’s ... Read more

October 6, 2016October 6, 2016

Clinical Trial of Potential Ulcerative Colitis Treatment Enters Next Phase

News

Theravance Biopharma announced the first dosing of a patient with moderate to severe ulcerative colitis enrolled in its Phase 1b clinical trial, which is evaluating the investigational drug TD-1473, a pan-Janus kinase (JAK) ... Read more

June 14, 2016June 14, 2016

Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD

IBD News, News, Ulcerative colitis

Theravance Biopharma, Inc., recently reported positive data from its Phase 1 clinical trial assessing TD-1473, a new and oral pan-Janus kinase (JAK) inhibitor designed to enter the gastrointestinal tract and target inflammation without significant ... Read more

November 5, 2015November 5, 2015

Theravance Biopharma Submits IBD Drug for FDA Investigational Approval

News

Theravance Biopharma, Inc., a company focused on underserved markets related to infectious diseases, lung and gastrointestinal tract disorders, recently announced in a press release the submission of an investigational new ... Read more